Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Receivables (2017 - 2024)

Serina Therapeutics' Receivables history spans 8 years, with the latest figure at $65000.0 for Q1 2024.

  • For Q1 2024, Receivables rose 983.33% year-over-year to $65000.0; the TTM value through Mar 2024 reached $65000.0, up 983.33%, while the annual FY2023 figure was $57000.0, 1325.0% up from the prior year.
  • Receivables for Q1 2024 was $65000.0 at Serina Therapeutics, up from $57000.0 in the prior quarter.
  • Across five years, Receivables topped out at $406000.0 in Q1 2020 and bottomed at $1000.0 in Q3 2022.
  • The 5-year median for Receivables is $66000.0 (2023), against an average of $128375.0.
  • The largest annual shift saw Receivables crashed 98.95% in 2022 before it surged 6600.0% in 2023.
  • A 5-year view of Receivables shows it stood at $397000.0 in 2020, then tumbled by 76.07% to $95000.0 in 2021, then plummeted by 95.79% to $4000.0 in 2022, then surged by 1325.0% to $57000.0 in 2023, then grew by 14.04% to $65000.0 in 2024.
  • Per Business Quant, the three most recent readings for SER's Receivables are $65000.0 (Q1 2024), $57000.0 (Q4 2023), and $67000.0 (Q3 2023).